Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RRV-IRF8
- Development stage
- Preclinical
- Lead developer
- University of California, San Francisco
- Modality
- Gene Therapies
- Administration
- Intratumoral
01
Overview
RRV-IRF8 is a retroviral replicating vector (RRV) designed to deliver Interferon Regulatory Factor 8 (IRF8), a master transcription factor regulating type 1 conventional dendritic cell (cDC1) development. Developed by researchers at the University of California, San Francisco (UCSF), RRV-IRF8 is designed to target and reprogram proliferating immunosuppressive myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages within the glioblastoma (GBM) tumor immune microenvironment into functional antigen-presenting cells (APCs). This reprogramming reduces myeloid-mediated immunosuppression, enhances antigen presentation, and promotes the recruitment and activation of cytotoxic CD8+ T cells, thereby restoring anti-tumor adaptive immunity.
Beyond the preview
Go deeper on RRV-IRF8.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RRV-IRF8.